Lopsided Solution: On Syrup-Based Medicines, Doctor’s Prescription

Editorial-19/06/2026

Lopsided Solution: On Syrup-Based Medicines, Doctor’s Prescription

In a bid to restore trust in India’s pharmaceutical sector after a string of child fatalities linked to contaminated cough syrups, the Union Health Ministry has mandated that all syrup-based medicines—including cough syrups—require a doctor’s prescription. By removing the word “syrup” from Entry 7 of Schedule K of the Drugs Rules, 1945, the government has effectively ended their over-the-counter (OTC) sale. While the move addresses immediate safety concerns, it offers a lopsided solution that prioritizes access restriction over the root problem: weak regulatory oversight of drug quality.

The Tragedy That Prompted the Ban
The decision follows a devastating series of incidents. Since 2022, more than 140 child deaths abroad have been linked to India-made syrups contaminated with diethylene glycol (DEG) and ethylene glycol (EG)—toxic solvents sometimes used as cheap substitutes for pharmaceutical-grade solvents. The Coldrif (also spelled Coldif) syrup tragedy in Madhya Pradesh and Rajasthan, where children died after consuming the product, triggered a World Health Organization (WHO) warning. The WHO identified three contaminated syrups—ColdRif, Respifresh TR, and ReLife—linked to deadly kidney illness in children.
These incidents tarnished India’s reputation as the “pharmacy of the world,” undermining confidence in a sector that supplies 20% of global vaccine demand and accounts for 13% of the world’s pharmaceutical production.

What the New Rule Actually Changes
Under the Drugs (Fifth Amendment) Rules, 2026, effective mid-June 2026:

Previous Status	New Status
Syrups categorised as OTC “household remedies”	All syrups require Registered Medical Practitioner (RMP) prescription
Chemists could sell without prescription	Chemists must verify valid prescription before dispensing
Pediatric cold/flu syrups exempt	Pediatric pain, fever, cold syrups now prescription-only
Only certain opioid syrups controlled	All syrup-based medicines, including opioid-containing ones, restricted

Even simple liquid oral suspensions of paracetamol and ibuprofen for children, previously exempt, now require prescription.

The Editorial’s Core Critique: A Lopsided Approach
The Hindu’s editorial argues that while mandating prescriptions may reduce self-medication and misuse, it fails to prevent contaminated products from entering the market. The solution is “lopsided” because:

It treats access, not quality
DEG contamination occurs during manufacturing, not at the point of sale. A prescription barrier cannot stop toxic solvents from being used in production. Without stronger manufacturing audits, the same contaminated syrups could still reach hospitals and clinics.
It ignores regulatory capacity gaps
Many state drug authorities lack skilled manpower and modern testing facilities. Rule enforcement is poor, and inspection frequency is inadequate. The editorial notes that India must “strengthen pharmaceutical regulatory oversight” rather than merely restricting access.
It creates unnecessary barriers for genuine patients
OTC cough syrups often contain antihistamines, decongestants, and cough suppressants that can cause side effects—tremors, heart palpitations, sedation, agitation in infants, and blood pressure fluctuations. Yet for many families, especially in rural areas with limited doctor access, requiring a prescription adds cost, time, and logistical burden for minor ailments.
It overlooks longstanding medical concerns about syrup formulations
Medical professionals have long questioned the formulation and临床应用 of many OTC cough syrups. Many are multicomponent mixtures with unclear efficacy. The prescription requirement should be accompanied by clinical guidelines on when syrups are truly necessary.

What a Balanced Solution Would Require
A comprehensive approach must address both quality and access:

Priority	Action
Manufacturing oversight	Mandatory batch-testing for DEG/EG; third-party audits; real-time purity monitoring
Regulatory capacity	Invest in state drug testing labs; train more inspectors; digitify inspection records
Enforcement	Penalize manufacturers using toxic solvents; impose license suspension for violations
Transparency	Public alert system for contaminated batches; QR-code traceability on syrup packs
Clinical guidance	Issue guidelines on syrup use vs. alternatives; educate doctors on safer formulations
Access equity	Allow telemedicine prescriptions for rural patients; exempt essential pediatric syrups under strict monitoring

Conclusion
The prescription mandate is a necessary but insufficient response. It addresses the symptom (unregulated access) while ignoring the disease (contaminated manufacturing). A truly effective solution must strengthen pharmaceutical regulatory oversight, ensure batch-level quality control, and build state-level regulatory capacity. Until India fixes the root cause, any measure remains, as the editorial aptly calls it, a lopsided solution.

Download Pdf

Student Login